ComplianceOnline

Risk Information in Prescription Drug & Medical Device Ads, Promotional Labeling – What the FDA Expects

  • By: Staff Editor
  • Date: November 17, 2011
Webinar All Access Pass Subscription Abstract:

The FDA has issued a draft guidance document on how manufacturers should present risk information in promotional material and ads for prescription drugs and medical devices. It describes the factors that the agency takes into consideration when evaluating ads and promotional labeling for prescription drugs and medical devices.

This article gives an overview and summary of the recommendations included in the FDA guidance.

Bookmark and Share

Trending Compliance Trainings

HVAC and GMP Environmental Control - for Pharmaceutical Cleanrooms
By - Roger Cowan
On Demand Access Anytime
Extractables and Leachables in Early Phase Development
By - Wayland Rushing
On Demand Access Anytime
CGMP controlled Raw Materials
By - Charity Ogunsanya
On Demand Access Anytime
OTC Drug Regulations
By - Loren Gelber
On Demand Access Anytime
Veterinary Feed Directive (VFD) Final Rule - What you need to know
By - Bernadette Alisantosa
On Demand Access Anytime
Best Sellers
You Recently Viewed
    Loading